Daily Sedative Interruption in Critically Ill Patients Being Managed With a Sedation Protocol
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
All critically ill, mechanically ventilated patients in the Intensive Care Unit receive medications to relieve pain and anxiety. However, accumulation of these medications can be associated with serious complications, most notably longer time on the breathing machine and in the ICU. Two strategies have been shown to dramatically improve patient outcomes: nurse-directed protocols for giving sedation, and daily interruption of sedation. However, these strategies have not been widely adopted, because of physicians' concerns, and because it is unclear which strategy is better. Given that patient outcome is improved with either of these strategies, the fundamental question that arises is whether patients managed with a combination of two strategies which both reduce drug accumulation (protocolized sedation and daily interruption) have an even better outcome than patients managed with only one of them (protocolized sedation). We propose a multicenter study in which 700 critically ill, mechanically ventilated patients will have their sedation managed with protocolized sedation alone, or both strategies. Both groups of patients will have the following recorded: ICU and hospital lengths of stay, mortality, total sedative drug use, ICU human resources used, side effects and recall of their ICU stay. The results of this large multi-center trial will help to inform best practice with regard to sedation management of critically ill patients in Canada and elsewhere. In addition, reducing ICU stay could be economically attractive, as the cost of an ICU day in Canada is approximately $3000.
| Condition | Intervention | Phase |
|---|---|---|
|
Critical Illness Mechanical Ventilation |
Procedure: Sedation management strategy |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Randomized Trial of Daily Sedative Interruption in Critically Ill Patients Being Managed With a Sedation Protocol - A Pilot Study |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age>18 years
- Mechanically ventilated, with anticipated need for MV ≥ 48 hours
- ICU team has decided to initiate continuous sedative/analgesic infusion(s)
- informed consent.
Exclusion Criteria:
- Admission after resuscitation from cardiac arrest
- Traumatic brain injury
- Currently receiving neuromuscular blocking agents
- Allergy to any of the study medications
- History of alcohol, sedative or analgesic abuse
- History of psychiatric illness
- Acute or chronic neurologic dysfunction
- Administration of sedatives for >24 hr,
- Lack of commitment to aggressive treatment
- Current enrollment in a related trial
- Previous enrollment in this trial.
Contacts and Locations| Canada, Ontario | |
| Mount Sinai Hospital | |
| Toronto, Ontario, Canada, M5G 1X5 | |
| Principal Investigator: | Sangeeta Mehta, MD | Mount Sinai Hospital, New York |
More Information
No publications provided by Mount Sinai Hospital, Canada
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00298493 History of Changes |
| Other Study ID Numbers: | MSH REB#00-0032-A |
| Study First Received: | February 28, 2006 |
| Last Updated: | February 28, 2006 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Mount Sinai Hospital, Canada:
|
ICU Sedation strategies Daily sedative interruption Sedation protocols |
Additional relevant MeSH terms:
|
Critical Illness Disease Attributes Pathologic Processes Hypnotics and Sedatives Central Nervous System Depressants |
Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013